InsiderTrades

Form 4 for ICUI ICU MEDICAL INC/DE

Accepted 2026-03-16 00:00:00 ET · period of report 2026-03-15 · accession 0001669639-26-000002 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-03-16 2026-03-15 ICUI Sanzone Virginia Ruth VP, GC F - Tax $125.85 -4,047 21.2K -16% -$509.3K
DM 2026-03-16 2026-03-15 ICUI Sanzone Virginia Ruth VP, GC M - OptEx $0.00 +7,324 24.3K +43% $0
DM 2026-03-16 2026-03-15 ICUI Sanzone Virginia Ruth VP, GC M - OptEx $0.00 -7,324 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-15 F D 897 $125.85 21,907 D — —
2 Common Common Stock 2026-03-15 M A 1,624 $0.00 22,804 D — — (F3) These securities are Restricted Stock Units.
3 Common Common Stock 2026-03-15 F D 3,150 $125.85 21,180 D — — (F1) These Securities are Performance-based Restricted Stock Units (PRSU).
4 Common Common Stock 2026-03-15 M A 5,700 $0.00 24,330 D — — (F1) These Securities are Performance-based Restricted Stock Units (PRSU). (F2) Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein.
5 Derivative Common Stock 2026-03-15 M D 1,624 $0.00 0 D $0.00 · 2026-03-15 to 2026-03-15 1,624 Common Stock (F3) These securities are Restricted Stock Units. (F4) There is neither a purchase price nor an exercise price for the Restricted Stock Units.
6 Derivative Performance Shares 2026-03-15 M D 5,700 $0.00 0 D $0.00 · 2026-03-15 to 2026-03-15 5,700 Common Stock (F1) These Securities are Performance-based Restricted Stock Units (PRSU). (F2) Represents the settlement of performance stock units granted on 3/15/2023. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 117% of target, resulting in the acquisition of the shares reported herein. (F5) There is neither a purchase price nor an exercise price for the PRSUs.